2024
Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Bharadwaj A, Abu-Much A, Maini A, Zhou Z, Li Y, Batchelor W, Grines C, Baron S, Redfors B, Lansky A, Basir M, O’Neill W. Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Circulation Cardiovascular Interventions 2024, 17: e013503. PMID: 38708609, PMCID: PMC11239095, DOI: 10.1161/circinterventions.123.013503.Peer-Reviewed Original ResearchChronic kidney diseaseHigh-risk percutaneous coronary interventionPercutaneous coronary interventionAdvanced chronic kidney diseaseIII studiesCerebrovascular eventsAngiographic characteristicsClinical outcomesCoronary calcificationCoronary interventionSevere coronary calcificationCardiac Surgery scoreHigh-risk patientsLong-term outcomesPercutaneous coronary intervention complicationsPCI-related complicationsPrevalence of hypertensionPeripheral arterial diseaseCoronary complicationsBaseline comorbiditiesSurgery scoreArtery diseasePrimary outcomeEGFRKidney disease
2023
Characteristics and outcomes of elderly patients undergoing protected percutaneous coronary intervention with impella mechanical circulatory support
Jakob P, Falah B, Abu-Much A, Lansky A, Basir M, Schonning M, Zhou Z, Batchelor W, Grines C, O'neill W, Stahli B. Characteristics and outcomes of elderly patients undergoing protected percutaneous coronary intervention with impella mechanical circulatory support. European Heart Journal 2023, 44: ehad655.2209. DOI: 10.1093/eurheartj/ehad655.2209.Peer-Reviewed Original ResearchHigh-risk percutaneous coronary interventionPercutaneous coronary interventionMechanical circulatory supportYears of ageCirculatory supportMyocardial infarctionCoronary interventionElderly patientsClinical outcomesStroke/transient ischemic attackMain percutaneous coronary interventionMultivariable Cox regression modelsSevere valvular heart diseaseLeft ventricular ejection fractionLower body mass indexBaseline SYNTAX scoreTransient ischemic attackHigh-risk patientsGlomerular filtration ratePrior myocardial infarctionVentricular ejection fractionValvular heart diseaseBody mass indexCox regression modelRisk of mortalityPredictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd point
2022
Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy
Erdogan E, Bajaj R, Lansky A, Mathur A, Baumbach A, Bourantas C. Intravascular Imaging for Guiding In‐Stent Restenosis and Stent Thrombosis Therapy. Journal Of The American Heart Association 2022, 11: e026492. PMID: 36326067, PMCID: PMC9750080, DOI: 10.1161/jaha.122.026492.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary interventionStent failureStent restenosisStent thrombosisSecond-generation drug-eluting stentsConventional percutaneous coronary interventionHigh-risk patientsBetter clinical outcomesLong-term outcomesDrug-eluting stentsCumulative incidenceClinical outcomesWorse prognosisProcedural resultsComplex anatomyEndovascular devicesRestenosisTherapyStent technologyDrug kineticsIntravascular imagingTreatment planningNeointima tissueThrombosisPCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes
Ahmad Y, Petrie M, Jolicoeur E, Madhavan M, Velazquez E, Moses J, Lansky A, Stone G. PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100020. PMID: 39132568, PMCID: PMC11307477, DOI: 10.1016/j.jscai.2022.100020.Peer-Reviewed Original ResearchPercutaneous coronary interventionLeft ventricular systolic dysfunctionCoronary artery diseaseHeart failureComplete revascularizationMedical therapyClinical outcomesClinical trialsCoronary artery bypassVentricular systolic dysfunctionClinical trial evidenceHigh operative riskHigh-risk patientsMajor cardiac surgeryExtent of revascularizationMinority of patientsFuture clinical trialsArtery bypassCause mortalityPeriprocedural complicationsSystolic dysfunctionCoronary interventionOperative riskArtery diseaseCardiac surgery
2020
Chapter 41 Embolic protection devices for stroke prevention during cardiac interventions
Ghare M, Zhou S, Tirziu D, Lansky A. Chapter 41 Embolic protection devices for stroke prevention during cardiac interventions. 2020, 941-960. DOI: 10.1016/b978-0-12-813704-8.00041-3.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationAortic stenosisSevere symptomatic aortic stenosisSurgical aortic valve replacementSymptomatic aortic stenosisAortic valve replacementHigh-risk patientsPrevention of strokeAortic valve implantationEmbolic protection devicesNeurologic eventsStroke preventionDevastating complicationIntermediate riskNeurologic injuryValve implantationValve replacementAdjunctive pharmacotherapyStroke rateCurrent evidenceTranscatheter proceduresCardiac interventionsPatientsStrokePrevention
2019
Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
Saito Y, Baumbach A, Wijns W, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent. Catheterization And Cardiovascular Interventions 2019, 96: 1023-1028. PMID: 31769161, DOI: 10.1002/ccd.28609.Peer-Reviewed Original ResearchConceptsHigh-risk patientsClinical outcomesComer studyI trialDurable polymer everolimus-eluting stentsTarget vessel myocardial infarctionSirolimus-eluting coronary stentYear clinical outcomesTarget lesion failureVessel myocardial infarctionLow-risk patientsWorse clinical outcomesEverolimus-eluting stentsHigh-risk groupLow-risk groupStrict eligibility criteriaFIREHAWK stentLesion failurePrimary endpointRandomized trialsMyocardial infarctionRisk groupsInclusion criteriaComplex lesionsXIENCE stent
2018
TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy.
Lansky A, Ghare MI, Tchétché D, Baumbach A. TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. EuroIntervention 2018, 14: ab53-ab63. PMID: 30158096, DOI: 10.4244/eij-d-18-00454.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic stenosisAdjunctive pharmacotherapySevere symptomatic aortic stenosisIntermediate-risk patientsSymptomatic aortic stenosisHigh-risk patientsAortic valve implantationSurgical valve replacementEvidence of neuroprotectionNeurologic eventsDevastating complicationNeurologic injuryValve implantationValve replacementCurrent evidenceNeuroprotectionPharmacotherapyPatientsPreferred methodComplicationsStenosisInjuryStrokeIncidence
2017
Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events The PROSPECT Study
Stone PH, Maehara A, Coskun AU, Maynard CC, Zaromytidou M, Siasos G, Andreou I, Fotiadis D, Stefanou K, Papafaklis M, Michalis L, Lansky AJ, Mintz GS, Serruys PW, Feldman CL, Stone GW. Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events The PROSPECT Study. JACC Cardiovascular Imaging 2017, 11: 462-471. PMID: 28917684, DOI: 10.1016/j.jcmg.2017.01.031.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary CirculationCoronary VesselsDisease ProgressionEndothelium, VascularEuropeHumansPercutaneous Coronary InterventionPilot ProjectsPlaque, AtheroscleroticPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsStress, MechanicalTime FactorsTreatment OutcomeUltrasonography, InterventionalUnited StatesConceptsMajor adverse cardiac eventsLow endothelial shear stressMinimum lumen areaAcute coronary syndromeEndothelial shear stressAdverse cardiac eventsPlaque burdenCoronary lesionsNC-MACECardiac eventsAnatomic riskNC lesionsFuture major adverse cardiac eventsHigh-risk acute coronary syndromesBaseline endothelial shear stressHuman-like animal modelsPrevious natural history studiesPropensity-adjusted Cox regressionSmaller minimum lumen areaPROSPECT studyLocal endothelial shear stressHigh anatomic riskHigh endothelial shear stressNonculprit coronary lesionsHigh-risk patients
2013
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stents
2012
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment optionsImplications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial
De Luca G, Brener SJ, Mehran R, Lansky AJ, McLaurin BT, Cox DA, Cristea E, Fahy M, Stone GW. Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial. International Journal Of Cardiology 2012, 167: 727-732. PMID: 22464479, DOI: 10.1016/j.ijcard.2012.03.058.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPercutaneous coronary interventionAcute coronary syndromeHigh-risk patientsTIMI flowACUITY trialCoronary syndromeMyocardial infarctionNon-ST segment elevation acute coronary syndromesST-segment elevation acute coronary syndromePost-PCI TIMI 3 flowElevation acute coronary syndromeIndependent angiographic core laboratoryPre-procedural TIMI flowBaseline TIMI flowPre-PCI TIMIPreprocedural TIMI flowTIMI 3 flowEarly invasive managementElevation myocardial infarctionNegative prognostic impactPercutaneous coronary revascularizationAngiographic core laboratoryReduced ThrombolysisTIMI 0/1
2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictors
2010
Surgical Versus Percutaneous Revascularization for Multivessel Disease in Patients With Acute Coronary Syndromes Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, Argenziano M, Williams MR, Colombo A, Aylward PE, Stone GW. Surgical Versus Percutaneous Revascularization for Multivessel Disease in Patients With Acute Coronary Syndromes Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. JACC Cardiovascular Interventions 2010, 3: 1059-1067. PMID: 20965465, DOI: 10.1016/j.jcin.2010.06.017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAcute Kidney InjuryAgedAngioplasty, Balloon, CoronaryBlood TransfusionCoronary AngiographyCoronary Artery BypassFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPropensity ScoreRecurrenceRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeHigh-risk patientsMultivessel diseaseACUITY trialRenal injuryMyocardial infarctionHigh-risk acute coronary syndromesAcute Coronary Syndromes AnalysisHigh-risk ACS patientsMultivessel coronary artery diseasePeri-procedural strokePreferred revascularization strategyPropensity-matched comparisonPropensity-matched patientsAcute renal injuryCoronary artery bypassOutcomes of patientsMore blood transfusionsCoronary artery diseaseRepeat revascularization proceduresACS patientsMajor bleedingPCI groupUnplanned revascularizationImpact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskWhen Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials
Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, Mehran R, Stone GW. When Is Door-to-Balloon Time Critical? Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. Journal Of The American College Of Cardiology 2010, 56: 407-413. PMID: 20650362, DOI: 10.1016/j.jacc.2010.04.020.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLower mortality rateHigh-risk patientsPercutaneous coronary interventionMortality rateEarly presentationCoronary interventionClinical riskST-segment elevation myocardial infarctionSimilar relative risk reductionsHORIZONS-AMI trialElevation myocardial infarctionRelative risk reductionNon-percutaneous coronary intervention hospitalsMortality rate reductionImpact of doorCADILLAC trialHORIZONS-AMIAntithrombotic therapyReperfusion therapyBalloon timeIntervention hospitalsAbsolute benefitLate presentationMyocardial infarction
2009
Treatment of left main and multivessel disease in the drug-eluting stent era.
Ng VG, Lansky AJ. Treatment of left main and multivessel disease in the drug-eluting stent era. Reviews In Cardiovascular Medicine 2009, 10 Suppl 2: s24-33. PMID: 19898278, DOI: 10.3909/ricm10s20004.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBypass surgeryMultivessel coronary artery diseaseCoronary artery bypass surgeryDrug-eluting stent eraArtery bypass surgeryHigh-risk patientsPercutaneous coronary interventionCoronary artery diseaseSignificant survival advantageAlternative treatment modalityStandard of careBare metal stentsMultivessel diseaseRepeat revascularizationCoronary interventionArtery diseaseMedical managementStent eraBalloon angioplastyNonrandomized studyLabel useTreatment modalitiesInvasive strategyClinical trialsEarly Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents
Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 687-698. PMID: 19171852, DOI: 10.1161/circulationaha.108.804203.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsAcute coronary syndromeGlycoprotein IIb/IIIa inhibitorsEarly stent thrombosisStent thrombosisCoronary syndromeBare metal stentsDrug-eluting stentsThienopyridine administrationAngiographic resultsHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialMetal stentsHigher baseline hemoglobin levelsInsulin-requiring diabetes mellitusQuantitative coronary angiographic analysisStent minimal lumen diameterAntiplatelet drug useBaseline renal insufficiencyCoronary angiographic analysisSuboptimal angiographic resultsBaseline hemoglobin levelDefinite stent thrombosisProbable stent thrombosisHigh-risk patients
2007
Impact of Time to Treatment on Myocardial Reperfusion and Infarct Size With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the EMERALD Trial)
Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky A, Na Y, Mehran R, Stone GW, Investigators E. Impact of Time to Treatment on Myocardial Reperfusion and Infarct Size With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the EMERALD Trial). The American Journal Of Cardiology 2007, 99: 1680-1686. PMID: 17560875, DOI: 10.1016/j.amjcard.2007.01.047.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPrimary PCIPercutaneous coronary interventionSmaller infarct sizeInfarct sizeNonanterior infarctionDistal protectionCoronary interventionMyocardial infarctionST-elevation myocardial infarctionHigh-risk patientsTriage of patientsAcute myocardial infarctionEMERALD trialImpact of timeControl patientsEarly reperfusionMyocardial reperfusionClinical outcomesAnterior infarctionMyocardial blushReperfusionInfarctionMortality ratePatients
2006
Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose.
Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose. The American Journal Of Cardiology 2006, 99: 315-321. PMID: 17261389, DOI: 10.1016/j.amjcard.2006.08.031.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAfrican American patientsMyocardial infarctionWhite patientsCoronary syndromeSegment elevation (NSTE) ACSST-segment elevation acute coronary syndromeElevation acute coronary syndromeBaseline clinical characteristicsFrequency of hypertensionNonfatal myocardial infarctionThirty-day deathCoronary artery bypassHigh-risk patientsOutcomes of patientsSanofi-AventisPercutaneous coronary interventionUse of angiographyNorth American patientsRacial differencesAfrican AmericansSYNERGY trialArtery bypassClinical characteristicsCoronary intervention